Login
Registrati
Reimposta password
Pubblica & Distribuisci
Soluzioni Editoriali
Soluzioni di Distribuzione
Temi
Architettura e design
Arti
Business e Economia
Chimica
Chimica industriale
Farmacia
Filosofia
Fisica
Geoscienze
Ingegneria
Interesse generale
Legge
Letteratura
Linguistica e semiotica
Matematica
Medicina
Musica
Scienze bibliotecarie e dell'informazione, studi library
Scienze dei materiali
Scienze della vita
Scienze informatiche
Scienze sociali
Sport e tempo libero
Storia
Studi classici e del Vicino Oriente antico
Studi culturali
Studi ebraici
Teologia e religione
Pubblicazioni
Riviste
Libri
Atti
Editori
Blog
Contatti
Cerca
EUR
USD
GBP
Italiano
English
Deutsch
Polski
Español
Français
Italiano
Carrello
Home
Riviste
Acta Pharmaceutica
Volume 74 (2024): Numero 1 (March 2024)
Accesso libero
A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality
Nem Kumar Jain
Nem Kumar Jain
,
Mukul Tailang
Mukul Tailang
,
Neelaveni Thangavel
Neelaveni Thangavel
,
Hafiz A. Makeen
Hafiz A. Makeen
,
Mohammed Albratty
Mohammed Albratty
,
Asim Najmi
Asim Najmi
,
Hassan Ahmad Alhazmi
Hassan Ahmad Alhazmi
,
Khalid Zoghebi
Khalid Zoghebi
,
Muthumanickam Alagusundaram
Muthumanickam Alagusundaram
,
Hemant Kumar Jain
Hemant Kumar Jain
e
Balakumar Chandrasekaran
Balakumar Chandrasekaran
| 30 mar 2024
Acta Pharmaceutica
Volume 74 (2024): Numero 1 (March 2024)
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Sommario
Bibliografia
Autori
Articoli in questo Numero
Anteprima
PDF
Cita
CONDIVIDI
Pubblicato online:
30 mar 2024
Pagine:
1 - 36
Accettato:
09 nov 2023
DOI:
https://doi.org/10.2478/acph-2024-0005
Parole chiave
FGFR
,
tyrosine kinase inhibitors
,
FDA approval
,
erdafitinib
,
infigratinib
,
pemigatinib
,
futibatinib
© 2024 Nem Kumar Jain et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Nem Kumar Jain
School of Pharmacy, ITM University Gwalior
India
School of Studies in Pharmaceutical Sciences, Jiwaji University Gwalior
India
Mukul Tailang
School of Studies in Pharmaceutical Sciences, Jiwaji University Gwalior
India
Neelaveni Thangavel
Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University
Saudi Arabia
Hafiz A. Makeen
Pharmacy Practice Research Unit Department of Clinical Pharmacy, College of Pharmacy, Jazan University
Saudi Arabia
Mohammed Albratty
Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University
Saudi Arabia
Asim Najmi
Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University
Saudi Arabia
Hassan Ahmad Alhazmi
Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University
Saudi Arabia
Khalid Zoghebi
Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University
Saudi Arabia
Muthumanickam Alagusundaram
School of Pharmacy, ITM University Gwalior
India
Hemant Kumar Jain
Department of General Medicine Government Medical College,
Datia, India
Balakumar Chandrasekaran
Faculty of Pharmacy, Philadelphia University
Amman, Jordan